50% off Premium Yearly
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.
Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.
It has no growth.
Build your watch list
Sign in to track investmentsyou care about
CNBC
RN Croft Financial Group
5i Research
Stockchase Premium
Private Wealth Management, ScotiaMcleod
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.